Cardlytics reported Q4 FY2025 results with total revenue of USD 56.1 million (down 24.2% YoY) and billings of USD 94.1 million (down 19.0% YoY). Adjusted Contribution was USD 31.7 million (down 22.1% YoY) and Adjusted EBITDA was USD 8.5 million (up 33.4% YoY). Net loss was USD 8.3 million, or USD 0.15 per share, while free cash flow was USD 10.5 million. For FY2025, Cardlytics posted total revenue of USD 233.3 million (down 16.2% YoY) and billings of USD 385.0 million (down 13.3% YoY). Net loss was USD 103.5 million (USD 1.95 per share), and Adjusted EBITDA was USD 10.1 million (up 298.6% YoY). FY2025 free cash flow was a loss of USD 6.5 million. Cardlytics’ Q4 MQUs were 227.0 million (up 18.4% YoY) and Q4 ACPU was USD 0.12 (down 35.0% YoY). Management said it took steps in 2025 to “reset” the business and improve financial health, and noted it is navigating an expected decrease in MQUs following the conclusion of Bank of America campaigns in January. For Q1 FY2026, Cardlytics guided for billings of USD 57.5 million to USD 63.5 million (down 41% to 35% YoY), revenue of USD 35.0 million to USD 40.0 million (down 43% to 35% YoY), Adjusted Contribution of USD 20.0 million to USD 23.0 million (down 38% to 29% YoY), and Adjusted EBITDA of a loss of USD 7.5 million to a loss of USD 3.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardlytics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603041602BIZWIRE_USPR_____20260304_BW946746) on March 04, 2026, and is solely responsible for the information contained therein.
Comments